Lv5
1110 积分 2023-10-24 加入
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
1个月前
已完结
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia
2个月前
已完结
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia
2个月前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
2个月前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
2个月前
已完结
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
3个月前
已完结
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
3个月前
已完结
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
3个月前
已完结
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
3个月前
已完结
皖公网安备34019202002308
